Fulgent Genetics

FLGT

Market cap $816M

Fulgent Genetics offers a fortress balance sheet, zero debt, and net assets near the current share price, providing downside protection. FLGT's diagnostics business is growing, with 15.4% revenue growth YTD and all segments contributing, notably BioPharma services up 72%. Management is highly aligned, owning 33% of shares, executing opportunistic buybacks, and prioritizing disciplined M&A for further growth.

ERO, NU, KSS, FLGT and BODI have been added to the Zacks Rank #1 (Strong Buy) List on Jan.12, 2026.

Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics (“Bako”), a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, MA. Fulgent will acquire.

Fulgent Genetics, Inc. ( FLGT ) UBS Global Healthcare Conference 2025 November 10, 2025 5:00 PM EST Company Participants Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lu Li - UBS Investment Bank, Research Division Presentation Lu Li UBS Investment Bank, Research Division Great. Well, our next session is the management team from Fulgent Genetics.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences: UBS Global Healthcare Conference on Monday, November 10th at 5:00 PM Eastern Time Piper Sandler 37th Annual Healthcare Conference on Tuesday, December.

Fulgent Genetics, Inc. ( FLGT ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Ming Hsieh - Chairman & CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lauren Sloane - The Blueshirt Group, LLC Lu Li - UBS Investment Bank, Research Division David Westenberg - Piper Sandler & Co., Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Presentation Operator Greetings, and welcome to the Fulgent Genetics Q3 2025 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to earnings of $0.31 per share a year ago.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2025. Third Quarter 2025 Results: Revenue of $84.1 million, growing 17% year-over-year GAAP loss of $6.6 million, or ($0.21) per share Non-GAAP income of $4.5 million, or $0.14 per share Adjusted EBI.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced preliminary clinical data as of September 25, 2025, the preliminary data cutoff from its ongoing phase 2 clinical trial investigating FID-007 in combination with cetuximab in ≤ 2nd line treatment of patients diagnosed with recurrent or metastatic head and neck.